GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause

GLP-1 agonists might affect the effectiveness of birth control pills, according to experts. A phase III trial of avexitide, a new type of GLP-1 receptor antagonist, successfully reduced low blood sugar events in patients with hypoglycemia following bariatric surgery. Eli Lilly has filed lawsuits against the illegal market for its weight-loss injectable retatrutide.

Researchers suggest that bone density loss alone may not fully explain the increased fracture risk in older adults with type 2 diabetes. The HHS has accused numerous hospitals and healthcare providers of billing issues related to gender-affirming care for minors, calling for a Justice Department investigation.

A survey of clinicians treating transgender and gender-diverse youth revealed varying emotions, from defeat to determination, as they navigate the current sociopolitical climate. Football player Nazeeh Johnson claimed a recent suspension under the NFL's performance-enhancing drug policy was due to a fertility medication.

AbCellera's investigational antibody ABCL635 significantly reduced the frequency and severity of moderate-to-severe menopause symptoms in a phase II study of postmenopausal women. Research from the SWAN study found that women exposed to the highest levels of air pollution went through natural menopause about a year earlier than those with lower pollution exposure.

Adults with a body mass index of 40 or higher have a higher risk of mortality compared to those with lower BMI, though this association weakens in older age groups, as per national health survey data.